$4.07
1.75% yesterday
Nasdaq, Oct 15, 10:00 pm CET
ISIN
US68621F1021
Symbol
ORGO

Organogenesis Holdings Stock price

$4.07
-0.89 17.94% 1M
-0.25 5.79% 6M
+0.87 27.19% YTD
+0.87 27.19% 1Y
+0.79 24.09% 3Y
-0.51 11.14% 5Y
-5.68 58.26% 10Y
-5.68 58.26% 20Y
Nasdaq, Closing price Wed, Oct 15 2025
+0.07 1.75%
ISIN
US68621F1021
Symbol
ORGO
Industry

Key metrics

Basic
Market capitalization
$516.3m
Enterprise Value
$444.6m
Net debt
positive
Cash
$73.1m
Shares outstanding
126.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.2 | 1.0
EV/Sales
1.0 | 0.9
EV/FCF
negative
P/B
1.4
Financial Health
Equity Ratio
77.4%
Return on Equity
-0.2%
ROCE
-3.7%
ROIC
-1.6%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$429.5m | $494.1m
EBITDA
$3.2m | $39.9m
EBIT
$-14.5m | $-4.4m
Net Income
$-15.6m | $-7.8m
Free Cash Flow
$-46.4m
Growth (TTM | estimate)
Revenue
-4.2% | 2.5%
EBITDA
-88.7% | 3.5%
EBIT
-221.4% | -120.6%
Net Income
5.6% | -725.5%
Free Cash Flow
-644.3%
Margin (TTM | estimate)
Gross
74.6%
EBITDA
0.7% | 8.1%
EBIT
-3.4%
Net
-3.6% | -1.6%
Free Cash Flow
-10.8%
More
EPS
$-0.1
FCF per Share
$-0.4
Short interest
24.7%
Employees
869
Rev per Employee
$550.0k
Show more

Is Organogenesis Holdings a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Organogenesis Holdings Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Organogenesis Holdings forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Organogenesis Holdings forecast:

Buy
88%
Hold
13%

Financial data from Organogenesis Holdings

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
430 430
4% 4%
100%
- Direct Costs 109 109
2% 2%
25%
320 320
5% 5%
75%
- Selling and Administrative Expenses 292 292
6% 6%
68%
- Research and Development Expense 43 43
15% 15%
10%
3.17 3.17
89% 89%
1%
- Depreciation and Amortization 18 18
10% 10%
4%
EBIT (Operating Income) EBIT -15 -15
221% 221%
-3%
Net Profit -16 -16
6% 6%
-4%

In millions USD.

Don't miss a Thing! We will send you all news about Organogenesis Holdings directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Organogenesis Holdings Stock News

Neutral
GlobeNewsWire
14 days ago
CANTON, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that third quarter of fiscal year 2025 financial results will be reported after the market clo...
Positive
Seeking Alpha
17 days ago
ORGO's AWC declined YoY, which is a significant headwind as it comprises the majority of its sales. However, the decline was mostly due to a delayed Medicare LCD, pressuring demand and product mix. Fortunately, the new LCD is a policy tailwind now. ORGO's Dermagraft and TransCyte reintroductions, plus FortiShield launch, also bode well for future growth in 2026.
Neutral
GlobeNewsWire
20 days ago
Company maintains confidence in ReNu as innovative pain management therapy Second Phase 3 trial demonstrates numerical improvement in baseline pain reduction over the first Phase 3 trial despite not meeting the primary endpoint Statistically significant maintenance of function (p
More Organogenesis Holdings News

Company Profile

Organogenesis Holdings, Inc. is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.

Head office United States
CEO Gary Gillheeney
Employees 869
Founded 1985
Website investors.organogenesis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today